KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $330.6 million.

  • Supernus Pharmaceuticals' Total Current Liabilities rose 1342.02% to $330.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.6 million, marking a year-over-year increase of 1342.02%. This contributed to the annual value of $292.4 million for FY2024, which is 75.85% up from last year.
  • Supernus Pharmaceuticals' Total Current Liabilities amounted to $330.6 million in Q3 2025, which was up 1342.02% from $286.4 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Total Current Liabilities peaked at $735.5 million during Q2 2022, and registered a low of $234.7 million during Q3 2021.
  • In the last 5 years, Supernus Pharmaceuticals' Total Current Liabilities had a median value of $291.5 million in 2024 and averaged $377.7 million.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Total Current Liabilities skyrocketed by 20931.1% in 2022, and later plummeted by 6565.91% in 2023.
  • Supernus Pharmaceuticals' Total Current Liabilities (Quarter) stood at $315.4 million in 2021, then surged by 118.14% to $688.0 million in 2022, then plummeted by 57.82% to $290.2 million in 2023, then increased by 0.76% to $292.4 million in 2024, then grew by 13.08% to $330.6 million in 2025.
  • Its last three reported values are $330.6 million in Q3 2025, $286.4 million for Q2 2025, and $281.8 million during Q1 2025.